Emerging biopharma companies are under pressure to spend carefully. That is hardly controversial. When you are a 40-person company working toward an investigational new drug (IND) filing, infrastructure does not compete for budget with other infrastructure. It competes with the next study.
So, a principle takes hold: spend as little as possible, as late as possible. It is sensible. Until “later” becomes expensive.
For years, that principle shaped how many emerging biopharma companies approached R&D IT. Buy what is needed now. Add the next system when the next requirement appears. Solve the integration problem when you have enough scale and budget to justify it.
An electronic lab notebook (ELN) here. A laboratory information management system (LIMS) is there. And a quality management system (QMS) before the audit. It works until it doesn’t.
The problem isn’t any one of those decisions. It’s what happens as they accumulate.
The real cost of a patchwork architecture is rarely visible when you buy the systems. It emerges later, in the gaps between them.
When people become the integration layer
When systems do not connect, people do.
They re-enter data, reconcile information, translate across functions, track down records, and answer questions about which version is current or where a specific piece of information is stored.
For a large organization, friction creates inefficiency. For an emerging biopharma company, it can stunt scalability.
And the problem is becoming harder to ignore.
Why waiting is becoming more expensive
Cell and gene therapies, complex biologics, and adaptive trial designs are generating greater volumes of increasingly complex data. As more information moves between systems and functions, manual handoffs and fragmented workflows become harder to rely on.
That changes the economics of waiting.
What appears to save money early can create costs elsewhere: manual effort, integration work, data reconciliation, compliance remediation, process redesign, or eventually replacing technology decisions that no longer fit the business.
The question is no longer, “Can we afford to build this now?”
It is increasingly, “What will it cost us if we build it later?”
Rethinking “as late as possible”
“Spend as little as possible, as late as possible” remains a sound principle. But not every investment benefits from delay. Some become more expensive precisely because they are postponed.
For emerging biopharma companies, the challenge is distinguishing the difference.
That does not mean building enterprise-scale infrastructure before the business needs it. It means making today’s technology decisions with tomorrow’s requirements in mind.
You don’t need to build a large IT organization to start making smarter technology decisions. You need to understand what your business requires today, what can wait, what needs to scale, and where delaying a decision could add cost or complexity down the road.
The goal isn’t to spend earlier for the sake of spending earlier. It’s to make better architecture decisions earlier.
Build for where you’re going, without overbuilding today
For some organizations, that may mean moving away from assembling disconnected point solutions and toward a more unified, cloud-native, and pre-validated architecture earlier in the company’s growth cycle.
A more connected data and technology architecture can reduce the manual effort required to move and reconcile information across functions. When implemented effectively, it can also make compliance less of a last-minute exercise and more of a foundational element of business operations.
But “future-ready” does not mean implementing everything at once.
Some capabilities may be essential today, while others may not be needed for years. Some systems may need to scale rapidly as the organization moves from research into clinical development and, eventually, to commercialization.
Knowing what to build now, what can wait, and how the pieces need to fit together is where specialist expertise is critical.
Even a single enterprise platform can eventually depend on dozens of integrations across data, applications, and business processes. For an emerging company, designing and managing that ecosystem internally may not be practical — nor does it necessarily make sense to build permanent headcount expertise that is most critical at specific points in the company’s growth.
The right expertise at the right time
A ten-person IT team shouldn’t have to hire its way into a sound technology architecture.
Emerging organizations may need deep architecture, platform, integration, PMO, or technology leadership at critical moments without needing or being ready for all those capabilities as permanent internal functions.
The question shifts from how quickly you can build an IT organization to how effectively you can access the expertise you need when you need it.
At BridgeView Life Sciences, we partner with pharma, biotech, and medical device organizations to bring together the technology, operations, and expertise needed to drive growth. Our team combines deep Life Sciences and platform experience with a flexible delivery model that meets organizations where they are, especially those lacking internal IT leadership, resources, or the capacity of a large enterprise.
That includes fractional CXO and PMO support, giving lean teams access to experienced technology and operational leadership without requiring them to build a large, permanent IT function. Because the goal isn’t to build a hypothetical enterprise years before you become one, it’s to make smarter decisions today that preserve your ability to become one tomorrow.
The companies that move ahead will not necessarily be those with the largest technology budgets. They may be the ones that recognize the cost of waiting before it hits the balance sheet.
And that may make “we’ll fix it later” some of the most expensive words in emerging biopharma.